GSK immunotherapy shows promise as alternative to surgery in certain rectal cancers

A small Memorial Sloan Kettering Cancer Center study found that all rectal cancer patients treated with GSK drug Jemperli showed a complete response at six months—there were no detectable signs of the cancer. These early data presented at ASCO suggest that rectal cancer with a particular genetic signature might be treatable with this immunotherapy in …

GSK immunotherapy shows promise as alternative to surgery in certain rectal cancers Read More »

ASCO recap: Breast cancer breakthrough, Mirati’s moves, Arcellx ascends & more

Breast cancer drugs and cell therapies were prominent in this year’s annual meeting of the American Society of Clinical Oncology. Here’s a recap of some of the news highlights from the biggest cancer conference of the year.

PMV’s ASCO data show signs of drugging ‘undruggable’ p53 protein across tumor types

PMV Pharmaceuticals has its first clinical data showing that its lead therapeutic candidate can hit p53, a tumor-suppressing protein long thought to be undruggable. After reporting the preliminary data during ASCO, PMV said it plans to continue Phase 1 study with the goal of advancing to Phase 2 early next year.

AstraZeneca, Daiichi Sankyo have high hopes for drug that goes low in breast cancer

During the annual meeting of the American Society of Clinical Oncology, AstraZeneca and Daiichi Sankyo reported pivotal clinical trial data showing that their partnered cancer drug Enhertu can treat a group of patients previously thought to be out of reach for a targeted therapy. The results suggest use of this FDA-approved drug could significantly expand …

AstraZeneca, Daiichi Sankyo have high hopes for drug that goes low in breast cancer Read More »

Gilead offers more detail on breast cancer drug’s trial results. Is it enough?

Gilead Sciences has more detail about breast cancer drug Trodelvy, a blockbuster hopeful it acquired two years ago. Additional data from a pivotal study were presented during the annual meeting of the American Society of Clinical Oncology and they still leave many questions unanswered.

Chicago, Philadelphia, LA County record first monkeypox cases

Chicago, Philadelphia and Los Angeles County all announced their first monkeypox cases Thursday amid growing concerns about the outbreak in the U.S. All three locations’ public health departments are currently awaiting final confirmation from the Centers for Disease Control and Prevention (CDC) for the presumed cases. “The patient is an adult resident who recently traveled …

Chicago, Philadelphia, LA County record first monkeypox cases Read More »

ASCO 2022 ahead: Clinical trial updates and data readouts to watch for

The American Society of Clinical Oncology’s annual meeting begins this week, including the presentation of more than 2,800 abstracts. Amgen, Roche, and Sierra Oncology are among the companies with key presentations at this year’s gathering.

Chicago’s O’Hare airport to enforce mask usage

Chicago’s O’Hare International Airport will continue to enforce masking despite multiple airlines dropping their requirements following a federal judge’s ruling. “The safety and security of passengers and employees is the highest priority for the Chicago Department of Aviation (CDA),” the airport said in a tweeted statement. “The CDA will continue to follow, observe and enforce …

Chicago’s O’Hare airport to enforce mask usage Read More »

Takeda returns to Evozyne’s AI tech, seeking novel proteins for next-gen gene therapies

Evozyne uses artificial intelligence and machine learning to design novel proteins that can be used in gene therapies. The new agreement with Takeda Pharmaceutical covers the development of proteins that can be used in gene therapies for rare diseases.

Digital tech for mental care grows as way to help patients navigate health deserts

The need for mental health services continues to strain the ability of the healthcare system to respond. New technologies are helping to improve patient access to care, and a panel at the MedCity INVEST conference in Chicago discussed the challenges and opportunities for these services.

As cash keeps pouring into health startups, VC firms work to stay disciplined

Venture capital investment in healthcare startups is continuing at a steady pace. Is it too much? Is a correction coming? Three investors offered their perspectives during a panel discussion at MedCity News’s INVEST conference in Chicago.

How payers are playing a part in new value-based outcomes strategies

Value-based healthcare puts the focus on patient outcomes, but payers have a part to play as well. A panel at MedCity News’ INVEST conference discussed how reimbursement strategies can improve patient care and reduce costs.

Diagnostic startups: Time is running out to apply to INVEST Pitch Perfect

The point of care diagnostics and testing market has climbed dramatically with the rise of the Covid-19 public health crisis. We’re seeking applications for diagnostics startups who would like to take part in INVEST Pitch Perfect Diagnostics 2.0 track at the conference, scheduled to take place March 28-30 in Chicago.

FDA has no appetite for Levo’s metabolic disorder drug and asks for new trial

The FDA rejected the new drug application for a Levo Therapeutics treatment for the rare metabolic disorder Prader-Willi syndrome. According to Levo, the agency said the data submitted were insufficient to support approval and the regulator wants the company to run another clinical trial.

Neuro startup Vanqua Bio emerges with $85M and a first focus on Parkinson’s

Vanqua Bio aims to treat rare form of Parkinson’s disease by boosting activity of an enzyme that is deficient in patients who have a particular genetic mutation. With $85 million in Series B financing, the biotech startup, which is based on Northwestern University research, aims to reach human testing within two years.

Leading hardtech innovation center mHUB opens MedTech accelerator for medical device startups [Sponsored]

The mHUB MedTech Accelerator is a six-month program, based in Chicago, run in partnership with Baxter and Edward-Elmhurst Health Venture Capital. The application deadline is Monday, August 23.

Ipsen bets on Exicure’s tech as better way to deliver neuro drugs deep into the brain

Ipsen is shoring up its neuroscience pipeline via a deal that gives it the option to license drugs that Exicure is developing for Huntington’s disease and Angelman syndrome. The programs are based on Exicure’s proprietary technology that produces nucleic acid therapies capable of delivery deep into the brain.

ASCO 2021 recap: Lynparza’s lift, Grail goes on, LAG validation & more

The American Society of Clinical Oncology’ annual meeting featured news highlights from the Merck, Novartis, and other drug giants. Meanwhile, some small biotechs rode the coattails of their larger counterparts and others forged their own paths with promising early results for new cancer drug targets.

Level Ex pitches gaming as a tool for reaching doctors

Interactive, cloud-based video games are designed to tackle pharma’s current challenge: engaging doctors virtually during a pandemic. But the tools are likely to outlive the circumstances in which they were born.